ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry O60840


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name CAC1F_HUMAN
Primary accession number O60840
Secondary accession numbers A6NI29 O43901 Q9UHB1
Integrated into Swiss-Prot on July 15, 1999
Sequence was last modified on April 14, 2009 (Sequence version 2)
Annotations were last modified on    June 16, 2009 (Entry version 92)
Name and origin of the protein
Protein name Voltage-dependent L-type calcium channel subunit alpha-1F
Synonym Voltage-gated calcium channel subunit alpha Cav1.4
Gene name
Name: CACNA1F
Synonyms: CACNAF1
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2), AND VARIANTS CSNB2A ASP-369; GLN-519; TRP-1060 AND HIS-1375.
TISSUE=Retina;
DOI=10.1038/940; PubMed=9662399 [NCBI, ExPASy, EBI, Israel, Japan]
Strom T.M., Nyakatura G., Apfelstedt-Sylla E., Hellebrand H., Lorenz B., Weber B.H.F., Wutz K., Gutwillinger N., Ruether K., Drescher B., Sauer C., Zrenner E., Meitinger T., Rosenthal A., Meindl A.;
"An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness.";
Nat. Genet. 19:260-263(1998).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
DOI=10.1006/geno.2000.6204; PubMed=10873387 [NCBI, ExPASy, EBI, Israel, Japan]
Naylor M.J., Rancourt D.E., Bech-Hansen N.T.;
"Isolation and characterization of a calcium channel gene, cacna1f, the murine orthologue of the gene for incomplete X-linked congenital stationary night blindness.";
Genomics 66:324-327(2000).
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
DOI=10.1038/nature03440; PubMed=15772651 [NCBI, ExPASy, EBI, Israel, Japan]
Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
"The DNA sequence of the human X chromosome.";
Nature 434:325-337(2005).
[4]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1211-1977 (ISOFORM 3).
DOI=10.1006/geno.1997.4941; PubMed=9344658 [NCBI, ExPASy, EBI, Israel, Japan]
Fisher S.E., Ciccodicola A., Tanaka K., Curci A., Desicato S., D'Urso M., Craig I.W.;
"Sequence-based exon prediction around the synaptophysin locus reveals a gene-rich area containing novel genes in human proximal Xp.";
Genomics 45:340-347(1997).
[5]
VARIANTS CSNB2A ASP-369; ASP-674 AND ASP-928.
DOI=10.1007/s004390100461; PubMed=11281458 [NCBI, ExPASy, EBI, Israel, Japan]
Boycott K.M., Maybaum T.A., Naylor M.J., Weleber R.G., Robitaille J., Miyake Y., Bergen A.A.B., Pierpont M.E., Pearce W.G., Bech-Hansen N.T.;
"A summary of 20 CACNA1F mutations identified in 36 families with incomplete X-linked congenital stationary night blindness, and characterization of splice variants.";
Hum. Genet. 108:91-97(2001).
[6]
VARIANTS CSNB2A ARG-74; PRO-229; ARG-261; ASP-369; CYS-753; PRO-860; ARG-1018; TRP-1060; PRO-1079; ARG-1499; ARG-1500 AND PRO-1508.
DOI=10.1038/sj.ejhg.5200828; PubMed=12111638 [NCBI, ExPASy, EBI, Israel, Japan]
Wutz K., Sauer C., Zrenner E., Lorenz B., Alitalo T., Broghammer M., Hergersberg M., de la Chapelle A., Weber B.H.F., Wissinger B., Meindl A., Pusch C.M.;
"Thirty distinct CACNA1F mutations in 33 families with incomplete type of XLCSNB and Cacna1f expression profiling in mouse retina.";
Eur. J. Hum. Genet. 10:449-456(2002).
[7]
VARIANTS CSNB2A ARG-150 AND ILE-635.
DOI=10.1076/opge.23.2.71.2214; PubMed=12187427 [NCBI, ExPASy, EBI, Israel, Japan]
Weleber R.G.;
"Infantile and childhood retinal blindness: a molecular perspective (The Franceschetti Lecture).";
Ophthalmic Genet. 23:71-97(2002).
[8]
VARIANT CSNB2A THR-756, AND CHARACTERIZATION OF VARIANT CSNB2A THR-756.
DOI=10.1073/pnas.0501907102; PubMed=15897456 [NCBI, ExPASy, EBI, Israel, Japan]
Hemara-Wahanui A., Berjukow S., Hope C.I., Dearden P.K., Wu S.-B., Wilson-Wheeler J., Sharp D.M., Lundon-Treweek P., Clover G.M., Hoda J.-C., Striessnig J., Marksteiner R., Hering S., Maw M.A.;
"A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation.";
Proc. Natl. Acad. Sci. U.S.A. 102:7553-7558(2005).
[9]
VARIANT THR-746.
DOI=10.1086/508067; PubMed=16960802 [NCBI, ExPASy, EBI, Israel, Japan]
Zeitz C., Kloeckener-Gruissem B., Forster U., Kohl S., Magyar I., Wissinger B., Matyas G., Borruat F.-X., Schorderet D.F., Zrenner E., Munier F.L., Berger W.;
"Mutations in CABP4, the gene encoding the Ca2+-binding protein 4, cause autosomal recessive night blindness.";
Am. J. Hum. Genet. 79:657-667(2006).
[10]
INVOLVEMENT IN CORDX3.
DOI=10.1136/jmg.2006.040741; PubMed=16505158 [NCBI, ExPASy, EBI, Israel, Japan]
Jalkanen R., Maentyjaervi M., Tobias R., Isosomppi J., Sankila E.-M., Alitalo T., Bech-Hansen N.T.;
"X linked cone-rod dystrophy, CORDX3, is caused by a mutation in the CACNA1F gene.";
J. Med. Genet. 43:699-704(2006).
[11]
INVOLVEMENT IN AIED.
DOI=10.1167/iovs.06-1103; PubMed=17525176 [NCBI, ExPASy, EBI, Israel, Japan]
Jalkanen R., Bech-Hansen N.T., Tobias R., Sankila E.-M., Maentyjaervi M., Forsius H., de la Chapelle A., Alitalo T.;
"A novel CACNA1F gene mutation causes Aland Island eye disease.";
Invest. Ophthalmol. Vis. Sci. 48:2498-2502(2007).
Comments
  • FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
  • SUBUNIT: Voltage-dependent calcium channels are multisubunit complexes, consisting of alpha-1, alpha-2, beta and delta subunits in a 1:1:1:1 ratio. The channel activity is directed by the pore-forming and voltage-sensitive alpha-1 subunit. In many cases, this subunit is sufficient to generate voltage-sensitive calcium channel activity. The auxiliary subunits beta and alpha-2/delta linked by a disulfide bridge regulate the channel activity. Interacts with CABP4 (By similarity).
  • INTERACTION:
    P06241:FYN; NbExp=1; IntAct=EBI-1757401, EBI-515315;
  • SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
  • ALTERNATIVE PRODUCTS: 3 named isoforms [FASTA] produced by alternative splicing.
    Name1
    Isoform IDO60840-1
    This is the isoform sequence displayed in this entry.
    Name2
    Isoform IDO60840-2
    Features which should be applied to build the isoform sequence: VSP_036785.
    Name3
    Isoform IDO60840-3
    Note: No experimental confirmation available.
    Features which should be applied to build the isoform sequence: VSP_036786, VSP_036787.
  • TISSUE SPECIFICITY: Expression in skeletal muscle and retina.
  • DOMAIN: Each of the four internal repeats contains five hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one positively charged transmembrane segment (S4). S4 segments probably represent the voltage-sensor and are characterized by a series of positively charged amino acids at every third position.
  • DISEASE: Defects in CACNA1F are the cause of congenital stationary night blindness type 2A (CSNB2A) [MIM:300071]. Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision.
  • DISEASE: Defects in CACNA1F are the cause of cone-rod dystrophy X-linked type 3 (CORDX3) [MIM:300476]. CORDs are inherited retinal dystrophies belonging to the group of pigmentary retinopathies. CORDs are characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa.
  • DISEASE: Defects in CACNA1F are the cause of Aaland island eye disease (AIED) [MIM:300600]; also called Forsius-Eriksson type ocular albinism. On the Aaland island in the Baltic Sea, AIED is an X-linked recessive retinal disease characterized by a combination of fundus hypopigmentation, decreased visual acuity due to foveal hypoplasia, nystagmus, astigmatism, protan color vision defect, myopia, and defective dark adaptation. Except for progression of axial myopia, the disease can be considered to be a stationary condition. Electroretinography reveals abnormalities in both photopic and scotopic functions.
  • SIMILARITY: Belongs to the calcium channel alpha-1 subunit (TC 1.A.1.11) family [view classification].
  • WEB RESOURCE: Name=Mutations of the CCNA1F gene; Note=Retina International's Scientific Newsletter; URL="http://www.retina-international.com/sci-news/cacnamut.htm";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
AJ006216; CAA06916.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AJ224874; CAA12175.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF201304; AAF15290.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF196779; -; NOT_ANNOTATED_CDS; Genomic_DNA.[EMBL / GenBank / DDBJ]
AF235097; -; NOT_ANNOTATED_CDS; Genomic_DNA.[EMBL / GenBank / DDBJ]
U93305; AAB92359.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
IPI IPI00465135; -.
IPI00924539; -.
IPI00925706; -.
RefSeq NP_005174.2; -.
UniGene Hs.632799
3D structure databases
ModBase O60840.
Protein-protein interaction databases
IntAct O60840; 1.
Protein family/group databases
TCDB 1.A.1.11.11; voltage-gated ion channel (VIC) superfamily.
1.A.1.11.15; voltage-gated ion channel (VIC) superfamily.
Organism-specific databases
GeneCards GC0XM048948; -.
HGNC HGNC:1393; CACNA1F.
GenAtlas CACNA1F.
MIM 300071; phenotype. [NCBI / EBI]
300110; gene. [NCBI / EBI]
300476; phenotype. [NCBI / EBI]
300600; phenotype. [NCBI / EBI]
Orphanet 1872; Cone rod dystrophy.
215; Night blindness, stationary, congenital.
PharmGKB PA26010; -.
Gene expression databases
ArrayExpress O60840; -.
Bgee O60840; -.
CleanEx HS_CACNA1F; -.
GermOnline ENSG00000102001; Homo sapiens.
Ontologies
GO
GO:0005891; Cellular component: voltage-gated calcium channel complex (inferred from direct assay from UniProtKB).
GO:0005509; Molecular function: calcium ion binding (inferred from electronic annotation from UniProtKB-KW).
GO:0015270; Molecular function: dihydropyridine-sensitive calcium channel activity (inferred from direct assay from UniProtKB).
GO:0005515; Molecular function: protein binding (inferred from physical interaction from IntAct).
GO:0006816; Biological process: calcium ion transport (inferred from electronic annotation from UniProtKB-KW).
GO:0050908; Biological process: detection of light stimulus involved in visual perception (inferred from mutant phenotype from UniProtKB).
QuickGo view.
Family and domain databases
InterPro IPR005821; Ion_trans.
IPR014873; VDCC_a1su_IQ.
IPR005446; VDCC_L_a1su.
IPR002077; VDCCAlpha1.
Graphical view of domain structure.
Pfam PF08763; Ca_chan_IQ; 1.
PF00520; Ion_trans; 4.
Pfam graphical view of domain structure.
PRINTS PR00167; CACHANNEL.
PR01630; LVDCCALPHA1.
Proteomic databases
PRIDE O60840; -.
Genome annotation databases
Ensembl ENSG00000102001; Homo sapiens. [Contig view]
GeneID 778; -.
Phylogenomic databases
HOVERGEN O60840; -.
OMA O60840; ETTLVEV.
Other
DrugBank DB00661; Verapamil.
SOURCE CACNA1F; Homo sapiens.
ProtoNet O60840.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
Alternative splicing; Calcium; Calcium channel; Calcium transport; Cone-rod dystrophy; Congenital stationary night blindness; Disease mutation; Disulfide bond; Glycoprotein; Ion transport; Ionic channel; Membrane; Phosphoprotein; Polymorphism; Repeat; Sensory transduction; Transmembrane; Transport; Vision; Voltage-gated channel.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom    To Length Description FTId
CHAIN   1   1977  1977     Voltage-dependent L-type calcium channel subunit alpha-1F. PRO_0000053950
TOPO_DOM   1     92  92     Cytoplasmic (Potential). 
TRANSMEM   93    111  19     S1 of repeat I (Potential). 
TOPO_DOM   112    129  18     Extracellular (Potential). 
TRANSMEM   130    149  20     S2 of repeat I (Potential). 
TOPO_DOM   150    161  12     Cytoplasmic (Potential). 
TRANSMEM   162    180  19     S3 of repeat I (Potential). 
TOPO_DOM   181    201  21     Extracellular (Potential). 
TRANSMEM   202    220  19     S4 of repeat I (Potential). 
TOPO_DOM   221    239  19     Cytoplasmic (Potential). 
TRANSMEM   240    259  20     S5 of repeat I (Potential). 
TOPO_DOM   260    347  88     Extracellular (Potential). 
TRANSMEM   348    372  25     S6 of repeat I (Potential). 
TOPO_DOM   373    529  157     Cytoplasmic (Potential). 
TRANSMEM   530    549  20     S1 of repeat II (Potential). 
TOPO_DOM   550    564  15     Extracellular (Potential). 
TRANSMEM   565    583  19     S2 of repeat II (Potential). 
TOPO_DOM   584    591  8     Cytoplasmic (Potential). 
TRANSMEM   592    610  19     S3 of repeat II (Potential). 
TOPO_DOM   611    620  10     Extracellular (Potential). 
TRANSMEM   621    639  19     S4 of repeat II (Potential). 
TOPO_DOM   640    658  19     Cytoplasmic (Potential). 
TRANSMEM   659    679  21     S5 of repeat II (Potential). 
TOPO_DOM   680    733  54     Extracellular (Potential). 
TRANSMEM   734    758  25     S6 of repeat II (Potential). 
TOPO_DOM   759    871  113     Cytoplasmic (Potential). 
TRANSMEM   872    890  19     S1 of repeat III (Potential). 
TOPO_DOM   891    906  16     Extracellular (Potential). 
TRANSMEM   907    926  20     S2 of repeat III (Potential). 
TOPO_DOM   927    938  12     Cytoplasmic (Potential). 
TRANSMEM   939    957  19     S3 of repeat III (Potential). 
TOPO_DOM   958    963  6     Extracellular (Potential). 
TRANSMEM   964    983  20     S4 of repeat III (Potential). 
TOPO_DOM   984   1002  19     Cytoplasmic (Potential). 
TRANSMEM   1003   1022  20     S5 of repeat III (Potential). 
TOPO_DOM   1023   1112  90     Extracellular (Potential). 
TRANSMEM   1113   1133  21     S6 of repeat III (Potential). 
TOPO_DOM   1134   1190  57     Cytoplasmic (Potential). 
TRANSMEM   1191   1209  19     S1 of repeat IV (Potential). 
TOPO_DOM   1210   1224  15     Extracellular (Potential). 
TRANSMEM   1225   1244  20     S2 of repeat IV (Potential). 
TOPO_DOM   1245   1251  7     Cytoplasmic (Potential). 
TRANSMEM   1252   1273  22     S3 of repeat IV (Potential). 
TOPO_DOM   1274   1290  17     Extracellular (Potential). 
TRANSMEM   1291   1310  20     S4 of repeat IV (Potential). 
TOPO_DOM   1311   1329  19     Cytoplasmic (Potential). 
TRANSMEM   1330   1349  20     S5 of repeat IV (Potential). 
TOPO_DOM   1350   1416  67     Extracellular (Potential). 
TRANSMEM   1417   1441  25     S6 of repeat IV (Potential). 
TOPO_DOM   1442   1977  536     Cytoplasmic (Potential). 
REPEAT   79    375  297     I. 
REPEAT   515    761  247     II. 
REPEAT   858   1140  283     III. 
REPEAT   1177   1444  268     IV. 
CA_BIND   1470   1481  12     By similarity. 
REGION   395    412  18     Binding to the beta subunit (By similarity). 
REGION   1060   1150  91     Dihydropyridine binding (By similarity). 
REGION   1397   1463  67     Dihydropyridine binding (By similarity). 
REGION   1409   1452  44     Phenylalkylamine binding (By similarity). 
COMPBIAS   659    665  7     Poly-Leu. 
COMPBIAS   794    799  6     Poly-Glu. 
COMPBIAS   809    825  17     Poly-Glu. 
COMPBIAS   1121   1124  4     Poly-Ile. 
COMPBIAS   1640   1645  6     Poly-Glu. 
SITE   330    330  1     Calcium ion selectivity and permeability (By similarity). 
SITE   711    711  1     Calcium ion selectivity and permeability (By similarity). 
SITE   1086   1086  1     Calcium ion selectivity and permeability (By similarity). 
SITE   1383   1383  1     Calcium ion selectivity and permeability (By similarity). 
MOD_RES   1452   1452        Phosphoserine; by PKA (Potential). 
CARBOHYD   295    295        N-linked (GlcNAc...) (Potential). 
VAR_SEQ   427    437        Missing (in isoform 2). VSP_036785
VAR_SEQ   1276   1282        Missing (in isoform 3). VSP_036786
VAR_SEQ   1663   1778        Missing (in isoform 3). VSP_036787
VARIANT   14     14  1     P -> L (in dbSNP:rs6520408 [NCBI]). VAR_030807 
VARIANT   74     74  1     C -> R (in CSNB2A). VAR_030808 
VARIANT   150    150  1     G -> R (in CSNB2A). VAR_030809 
VARIANT   229    229  1     S -> P (in CSNB2A). VAR_030810 
VARIANT   261    261  1     G -> R (in CSNB2A). VAR_030811 
VARIANT   369    369  1     G -> D (in CSNB2A). VAR_001504 
VARIANT   519    519  1     R -> Q (in CSNB2A; dbSNP:rs34162630 [NCBI]). VAR_001505 
VARIANT   635    635  1     V -> I (in CSNB2A). VAR_030812 
VARIANT   674    674  1     G -> D (in CSNB2A). VAR_030813 
VARIANT   746    746  1     N -> T. VAR_029376 
VARIANT   753    753  1     F -> C (in CSNB2A). VAR_030814 
VARIANT   756    756  1     I -> T (in CSNB2A; increases the number of mutant channels open at physiologic membrane potential and allows for persistent Ca(2+) entry due to reduced channel inactivation resulting in a gain-of-function defect). VAR_030815 
VARIANT   860    860  1     L -> P (in CSNB2A). VAR_030816 
VARIANT   928    928  1     A -> D (in CSNB2A). VAR_030817 
VARIANT   1018   1018  1     G -> R (in CSNB2A). VAR_030818 
VARIANT   1060   1060  1     R -> W (in CSNB2A). VAR_001506 
VARIANT   1079   1079  1     L -> P (in CSNB2A). VAR_030819 
VARIANT   1259   1259  1     A -> T (in dbSNP:rs34308720 [NCBI]). VAR_055662 
VARIANT   1270   1270  1     A -> T (in dbSNP:rs34308720 [NCBI]). VAR_031822 
VARIANT   1375   1375  1     L -> H (in CSNB2A). VAR_001507 
VARIANT   1499   1499  1     C -> R (in CSNB2A). VAR_030820 
VARIANT   1500   1500  1     P -> R (in CSNB2A). VAR_030821 
VARIANT   1508   1508  1     L -> P (in CSNB2A). VAR_030822 
VARIANT   1930   1930  1     R -> H (in dbSNP:rs33910054 [NCBI]). VAR_054818 
CONFLICT   1236   1236        E -> V (in Ref. 4; AAB92359). 
CONFLICT   1860   1860        A -> G (in Ref. 4; AAB92359). 
Sequence information
Length: 1977 AA [This is the length of the unprocessed precursor] Molecular weight: 220678 Da [This is the MW of the unprocessed precursor] CRC64: 354336550C6D8E73 [This is a checksum on the sequence]
        10         20         30         40         50         60 
MSESEGGKDT TPEPSPANGA GPGPEWGLCP GPPAVEGESS GASGLGTPKR RNQHSKHKTV 

        70         80         90        100        110        120 
AVASAQRSPR ALFCLTLANP LRRSCISIVE WKPFDILILL TIFANCVALG VYIPFPEDDS 

       130        140        150        160        170        180 
NTANHNLEQV EYVFLVIFTV ETVLKIVAYG LVLHPSAYIR NGWNLLDFII VVVGLFSVLL 

       190        200        210        220        230        240 
EQGPGRPGDA PHTGGKPGGF DVKALRAFRV LRPLRLVSGV PSLHIVLNSI MKALVPLLHI 

       250        260        270        280        290        300 
ALLVLFVIII YAIIGLELFL GRMHKTCYFL GSDMEAEEDP SPCASSGSGR ACTLNQTECR 

       310        320        330        340        350        360 
GRWPGPNGGI TNFDNFFFAM LTVFQCVTME GWTDVLYWMQ DAMGYELPWV YFVSLVIFGS 

       370        380        390        400        410        420 
FFVLNLVLGV LSGEFSKERE KAKARGDFQK QREKQQMEED LRGYLDWITQ AEELDMEDPS 

       430        440        450        460        470        480 
ADDNLGSMAE EGRAGHRPQL AELTNRRRGR LRWFSHSTRS THSTSSHASL PASDTGSMTE 

       490        500        510        520        530        540 
TQGDEDEEEG ALASCTRCLN KIMKTRVCRR LRRANRVLRA RCRRAVKSNA CYWAVLLLVF 

       550        560        570        580        590        600 
LNTLTIASEH HGQPVWLTQI QEYANKVLLC LFTVEMLLKL YGLGPSAYVS SFFNRFDCFV 

       610        620        630        640        650        660 
VCGGILETTL VEVGAMQPLG ISVLRCVRLL RIFKVTRHWA SLSNLVASLL NSMKSIASLL 

       670        680        690        700        710        720 
LLLFLFIIIF SLLGMQLFGG KFNFDQTHTK RSTFDTFPQA LLTVFQILTG EDWNVVMYDG 

       730        740        750        760        770        780 
IMAYGGPFFP GMLVCIYFII LFICGNYILL NVFLAIAVDN LASGDAGTAK DKGGEKSNEK 

       790        800        810        820        830        840 
DLPQENEGLV PGVEKEEEEG ARREGADMEE EEEEEEEEEE EEEEEGAGGV ELLQEVVPKE 

       850        860        870        880        890        900 
KVVPIPEGSA FFCLSQTNPL RKGCHTLIHH HVFTNLILVF IILSSVSLAA EDPIRAHSFR 

       910        920        930        940        950        960 
NHILGYFDYA FTSIFTVEIL LKMTVFGAFL HRGSFCRSWF NMLDLLVVSV SLISFGIHSS 

       970        980        990       1000       1010       1020 
AISVVKILRV LRVLRPLRAI NRAKGLKHVV QCVFVAIRTI GNIMIVTTLL QFMFACIGVQ 

      1030       1040       1050       1060       1070       1080 
LFKGKFYTCT DEAKHTPQEC KGSFLVYPDG DVSRPLVRER LWVNSDFNFD NVLSAMMALF 

      1090       1100       1110       1120       1130       1140 
TVSTFEGWPA LLYKAIDAYA EDHGPIYNYR VEISVFFIVY IIIIAFFMMN IFVGFVIITF 

      1150       1160       1170       1180       1190       1200 
RAQGEQEYQN CELDKNQRQC VEYALKAQPL RRYIPKNPHQ YRVWATVNSA AFEYLMFLLI 

      1210       1220       1230       1240       1250       1260 
LLNTVALAMQ HYEQTAPFNY AMDILNMVFT GLFTIEMVLK IIAFKPKHYF TDAWNTFDAL 

      1270       1280       1290       1300       1310       1320 
IVVGSIVDIA VTEVNNGGHL GESSEDSSRI SITFFRLFRV MRLVKLLSKG EGIRTLLWTF 

      1330       1340       1350       1360       1370       1380 
IKSFQALPYV ALLIAMIFFI YAVIGMQMFG KVALQDGTQI NRNNNFQTFP QAVLLLFRCA 

      1390       1400       1410       1420       1430       1440 
TGEAWQEIML ASLPGNRCDP ESDFGPGEEF TCGSNFAIAY FISFFMLCAF LIINLFVAVI 

      1450       1460       1470       1480       1490       1500 
MDNFDYLTRD WSILGPHHLD EFKRIWSEYD PGAKGRIKHL DVVALLRRIQ PPLGFGKLCP 

      1510       1520       1530       1540       1550       1560 
HRVACKRLVA MNMPLNSDGT VTFNATLFAL VRTSLKIKTE GNLEQANQEL RIVIKKIWKR 

      1570       1580       1590       1600       1610       1620 
MKQKLLDEVI PPPDEEEVTV GKFYATFLIQ DYFRKFRRRK EKGLLGNDAA PSTSSALQAG 

      1630       1640       1650       1660       1670       1680 
LRSLQDLGPE MRQALTCDTE EEEEEGQEGV EEEDEKDLET NKATMVSQPS ARRGSGISVS 

      1690       1700       1710       1720       1730       1740 
LPVGDRLPDS LSFGPSDDDR GTPTSSQPSV PQAGSNTHRR GSGALIFTIP EEGNSQPKGT 

      1750       1760       1770       1780       1790       1800 
KGQNKQDEDE EVPDRLSYLD EQAGTPPCSV LLPPHRAQRY MDGHLVPRRR LLPPTPAGRK 

      1810       1820       1830       1840       1850       1860 
PSFTIQCLQR QGSCEDLPIP GTYHRGRNSG PNRAQGSWAT PPQRGRLLYA PLLLVEEGAA 

      1870       1880       1890       1900       1910       1920 
GEGYLGRSSG PLRTFTCLHV PGTHSDPSHG KRGSADSLVE AVLISEGLGL FARDPRFVAL 

      1930       1940       1950       1960       1970 
AKQEIADACR LTLDEMDNAA SDLLAQGTSS LYSDEESILS RFDEEDLGDE MACVHAL 

O60840 in FASTA format

View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

BLAST logo BLAST submission on ExPASy/SIB
or at NCBI (USA)
Tools Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
PROSITE logo ScanProsite, MotifScan SWISS-MODEL Submit a homology modeling request to SWISS-MODEL
NPSA logo NPSA Sequence analysis tools

ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
 Hosted by ch flag SIB Switzerland Mirror sites: Australia  Brazil  Canada  China  Korea
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!